Clinical Trial Update: Cabozantinib in Combination With Avelumab in Patients Refractory to Standard Chemotherapy With Advanced Neuroendocrine Neoplasias G3 (NEN G3) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating cabozantinib plus avelumab in patients with advanced neuroendocrine neoplasias G3 refractory to standard chemotherapy.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neuroendocrine Neoplasia

Drugs mentioned

• cabozantinib + avelumab

Snippet

Sponsor: Johannes Gutenberg University Mainz | Conditions: Cancer | Phase 2 | Status: UNKNOWN